We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Anbio Biotechnology Presents Point-Of-Care IVD Solutions

By LabMedica International staff writers
Posted on 08 Feb 2024

Anbio Biotechnology (Frankfurt, Germany) is demonstrating its FIA, CLIA, LAMP, and dry chemistry analyzers, along with other easy-to-use diagnostic solutions, at Medlab Middle East 2024. More...

During the trade show, Anbio is showcasing its fluorescence immunoassay (FIA) solutions which include four types of analyzers, from portable handheld to bench-top sizes, as well as a wide range of assays. 78 available assays enable the detection of a variety of analytes, including hormones, cancer markers, cardiac markers, drugs of abuse, inflammation, and infectious diseases. Also on display is Anbio’s ADL i1910 chemiluminescence immunoassay analyzer which is designed to transform the landscape of clinical diagnostics. With an impressive range of 50 CE-marked assays, this fully automated, high throughput, compact CLIA analyzer supports both qualitative and quantitative testing of analytes.

At Medlab Middle East 2024, Anbio is presenting the SHA-100 small-sized, portable, and easy-to-use dry-chemistry analyzer that supports real-time testing and real-time printing of quantitative detection results for 18 test items. Anbio is also demonstrating its LAMP Solution, a diagnostic technique to amplify and detect specific DNA or RNA sequences that is used for various applications, including detecting infectious diseases, genetic disorders, and foodborne pathogens. Anbio’s LAMP solution offers miniaturized analyzers, which are extremely easy to use. The egg-shaped LAMP device is a one-button control capable of delivering fast, sensitive, and specific results for various infectious diseases. It is suitable for over-the-counter (OTC) and point-of-care (POC) diagnostics.

For the first time, Anbio is showcasing the ABO & Rhd Blood Grouping Kit, a qualitative detection test kit for the ABO and D antigen of the Rhd blood group system on human red blood cells in whole blood or 10% red cell suspensions in physiological saline. The ABO & Rhd Blood Grouping Kit is based on the principle of antigen-antibody dot immune filtration assay to provide convenience and accuracy in testing blood types for clinical use and emergencies. It can acquire accurate results from fresh fingertip blood in as little as one minute, with a storage time of 24 months, and does not require special refrigeration or cold-chain transportation. It can quickly display blood type information through paper strip reactions, representing a modern approach to blood type testing.

"Anbio is consistently dedicated to developing easy-to-access and reliable diagnostic test kits for improving user experience in various application scenarios," said Michael Lau, CEO of Anbio Biotechnology. "Anbio's ABO & Rhd Blood Grouping Kit provides a simple way for blood type testing with low requirements for user environment, storage, and transportation while ensuring the accuracy of the results. The target market of this product will be mainly focusing on the Middle East, Asia, and Africa regions. We will continue to invest in user-centric, affordable, and reliable Point-of-Care Testing solutions and bring them to the world."

Related Links:
Anbio Biotechnology


New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
New
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Capillary testing on the Atellica analyzers supports the most common laboratory testing needs (Photo courtesy of Siemens Healthineers)

Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers

Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
MEDLAB 2024
Copyright © 2000-2026 Globetech Media. All rights reserved.